ORIGINAL RESEARCH article

Front. Public Health

Sec. Health Economics

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1555444

This article is part of the Research TopicPublic Health Outcomes: The Role of Social Security Systems in Improving Residents' Health WelfareView all 55 articles

Evaluating the Impact of the Diagnosis-Related Groups Payment System on Laparoscopic Uterine Fibroid Surgery Outcomes: Insights from a Single-Center Study

Provisionally accepted
Jingjing  LuJingjing LuYiming  PanYiming PanLu  LiLu LiLili  ChuLili ChuYanshan  JinYanshan Jin*
  • Ningbo Yinzhou People's Hospital, Ningbo, China

The final, formatted version of the article will be published soon.

This study aimed to assess the impact of implementing the diagnosis-related groups (DRGs) payment system on hospitalization costs and medical service outcomes at a single institution. The objective was to identify effective cost-saving strategies and guide healthcare practices to support the ongoing adoption of the DRGs system.This retrospective study included 616 patients, categorized into three groups based on the payment system in effect during their treatment: a 6-month period under fee-for-service (FFS), a 6-month period following the trial implementation of DRGs (TI-DRGs), and a 6-month period after the official implementation of DRGs (OI-DRGs). Each group was further divided into two subgroups according to the surgical intervention received (either laparoscopic myomectomy or laparoscopic hysterectomy). Data collected included total medical costs, examination fees, surgical costs, medication and supply expenses, length of hospital stay, operation time, intraoperative blood loss, incidence of postoperative anemia, and frequency of blood transfusionsTotal medical costs in the OI-DRGs group were 6.6% and 9.0% higher than those in the FFS and TI-DRGs groups, respectively (P < 0.001). Examination costs followed a similar pattern, with the OI-DRGs group showing increases of 5.3% and 12.3% compared to the FFS and TI-DRGs groups (P < 0.001). Operation costs also varied significantly among the three groups; the OI-DRGs group incurred 17.1% and 10.5% higher costs than the FFS and TI-DRGs groups, respectively (P < 0.001).There were no significant differences among the groups in terms of hospital stay duration, operation time, or intraoperative blood loss. However, these differences were not statistically significant.In summary, the implementation of DRGs for laparoscopic uterine leiomyoma surgery did not lead to a significant reduction in total medical costs. Overall costs were influenced by multiple factors, including the DRG phase, length of stay, type of surgery, and the presence of concurrent procedures.The findings from our single-center study differ from the mainstream view, highlighting that the effects of DRG implementation can be highly context-specific, shaped by local policies, hospital practices, and patient case-mix, which may limit the generalizability of these results beyond our institution or region.

Keywords: Diagnosis-Related Groups, laparoscopic uterine fibroid surgery, Healthcare costs, surgical outcomes, Hospital resource utilization, payment systems

Received: 04 Jan 2025; Accepted: 28 May 2025.

Copyright: © 2025 Lu, Pan, Li, Chu and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yanshan Jin, Ningbo Yinzhou People's Hospital, Ningbo, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.